Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus DSUVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus DSUVIA.
DALGAN vs DSUVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Selective, high-affinity agonist at the mu-opioid receptor, resulting in analgesia via activation of G-protein coupled inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels in the central nervous system.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
30 mcg sublingual tablet as a single dose; may repeat once after 1 hour if needed. Maximum 2 doses per 24 hours.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Terminal elimination half-life is approximately 23.4 hours (range 17–30 h), supporting once-daily dosing. Due to rapid redistribution, clinical effects may wane before elimination is complete.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Primarily renal elimination of metabolites; unchanged drug accounts for <1% of the dose. Fecal excretion is minimal. Total recovery: ~70% in urine, ~20% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic